Metsera’s MET097 Phase 2b Obesity Trial Reaches Completion: What Investors Should Watch Next
Metsera, Inc. (MTSR) announced an update on their ongoing clinical study.
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The Phase 2b study VESPER-2, officially titled “A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight, and Type 2 Diabetes Mellitus (VESPER-2),” tests once-weekly MET097 in adults with obesity and type 2 diabetes. It aims to measure weight loss and blood sugar control versus placebo, an important step for Metsera, Inc. (MTSR) and its partners in a crowded metabolic market.
The main treatment is MET097, a drug given as a weekly injection under the skin. It is designed to act on the same pathway as GLP-1 medicines, with the goal of driving steady weight loss and better blood sugar control in patients who are overweight or have type 2 diabetes.
The trial is an interventional Phase 2b study with patients randomly assigned to MET097 or placebo in separate parallel groups. Both patients and investigators are blinded to which treatment is given, and the main goal is to see how well MET097 treats obesity and diabetes compared with placebo.
The study has been marked as completed, showing that patient dosing and main data collection are finished. The latest update to the trial record was submitted on 26 May 2026, signaling that data review or preparation for results disclosure is ongoing and that key readouts may follow.
For investors, a completed Phase 2b obesity and diabetes trial is a notable catalyst for MTSR because this category has driven large gains for peers such as Eli Lilly and Novo Nordisk. If MET097 data show competitive weight loss and safety, sentiment toward MTSR and any large-pharma partner could improve, while weak results could weigh on shares in a sector that now sets a high bar for new GLP-1 entrants.
The trial has been completed and recently updated, and further details are available on the ClinicalTrials portal.
To learn more about MTSR’s potential, visit the Metsera, Inc. drug pipeline page.
